Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $4.36M (cash outflow) fell 24.7% year over year, behind the +453.0% change in trailing-twelve-month accounts receivables. Sequentially, it fell 78.3% from the prior quarter. Over 3 fiscal years it compounded at +151.8% a year.
Context
- Accounts receivables amounted to 10.4% of revenue in FY2025, up 7.9 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -24.7% toward the trailing-twelve-month pace of +453.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (61M) USD
- Year-over-year change
- -410.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61M) | -410.0% |
| FY2024 | 2024-12-31 | (11.96M) | +72.2% |
| FY2023 | 2023-12-31 | (43.08M) | -1027.6% |
| FY2022 | 2022-12-31 | (3.82M) | -504.4% |
| FY2021 | 2021-12-31 | (632K) | — |
Accounts Receivables vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 accounts receivables of $59.57M is the largest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of +453.0% is the highest of 7, against a peer median of -47.1%.
- Accounts receivables amounts to 10.0% of revenue for CPRX, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.57M | +453.0% | +151.8% | 10.0% | |
| LTM Mar 2026 | $12.79M | -11832.1% | +43.1% | 19.4% | |
| LTM Jun 2026 | $11.15M | -54.5% | — | 20.3% | |
| LTM Jun 2026 | $8.42M | +173.5% | — | 1.0% | |
| LTM Jun 2026 | $5.23M | -39.7% | -27.5% | 1.7% | |
| LTM Sep 2026 | $677K | — | — | 118.8% | |
| LTM Jun 2026 | $165K | +123.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CPRX) | $0 | -47.1% | +7.8% | 1.7% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| Deferred Income Tax | 9.32M | 4.94M | (17.82M) | (9.39M) | (6.85M) |
| Stock-Based Compensation | 6.07M | 7.91M | 14.25M | 22.25M | 24.78M |
| Change in Working Capital | 5.02M | 13.73M | (37.32M) | 30.91M | (60.9M) |
| Accounts Receivables | (632K) | (3.82M) | (43.08M) | (11.96M) | (61M) |
| Inventory | (3.22M) | 1.07M | (4.74M) | (3.9M) | (18.09M) |
| Accounts Payables | (1.49M) | 1.21M | 10.82M | 1.8M | (5.39M) |
| Other Working Capital | 10.36M | 15.28M | (330K) | 44.98M | 23.59M |
| Other Non-Cash Items | 287K | 5.16M | 80.2M | (5.63M) | (563K) |
| Operating Cash Flow | 60.37M | 116.05M | 143.6M | 239.81M | 208.67M |
| Capital Expenditures | (1.02M) | (29K) | (81.74M) | (556K) | (58K) |
| Acquisitions (Net) | 0 | 10M | 0 | 0 | 0 |
| Purchases of Investments | (10M) | (10M) | (13.47M) | 0 | 0 |
| Sales of Investments | 0 | 19.24M | 0 | 0 | 0 |
| Other Investing Activities | 0 | (10M) | (279.81M) | 0 | 0 |
| Investing Cash Flow | (11.02M) | 9.21M | (293.5M) | (556K) | (58K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.1M | 9.57M | 2.79M | 141M | 14.67M |
| Common Stock Repurchased | (12.09M) | (6.91M) | 0 | (296K) | (25.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (153K) | (968K) | (13.65M) | (39K) | (6.36M) |
| Financing Cash Flow | (8.14M) | 1.69M | (10.86M) | 140.67M | (16.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.21M | 126.95M | (160.76M) | 379.92M | 191.62M |
| Free Cash Flow | 59.35M | 116.02M | 61.86M | 239.25M | 208.61M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.